Trials / Conditions / Triple Negative Metastatic Breast Cancer
Triple Negative Metastatic Breast Cancer
6 registered clinical trials studyying Triple Negative Metastatic Breast Cancer.
| Status | Trial | Sponsor | Phase |
|---|---|---|---|
| Completed | CISPLATIN + AZD-1775 In Breast Cancer NCT03012477 | Dana-Farber Cancer Institute | Phase 2 |
| Terminated | Study of BMN-673 With Carboplatin and Paclitaxel in Patients With Advanced BRCA-mutated Solid Tumor or Triple NCT02358200 | Pamela Munster | Phase 1 |
| Completed | Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabin NCT01881230 | Celgene | Phase 2 / Phase 3 |
| Completed | Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumo NCT01576666 | Novartis Pharmaceuticals | Phase 1 |
| Terminated | Bevacizumab + Paclitaxel + Capecitabine in Triple Negative Metastatic Breast Cancer NCT01069796 | ARCAGY/ GINECO GROUP | Phase 2 |
| Completed | Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Carboplatin and/or Paclita NCT00516724 | AstraZeneca | Phase 1 |